2. Neurological Disease

Neurological Disease

Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160663
    Nav1.7 blocker 1 1426336-36-8
    Nav1.7 blocker 1 (example 41) is a Na+ channel (Nav) blocker with an IC50 value of 0.037 μM. Nav1.7 blocker 1 can be used for the study of pain, including neuropathic pain, postoperative pain, inflammatory pain, and so on.
    Nav1.7 blocker 1
  • HY-160668
    Histamine H3 antagonist-1 1000392-25-5
    Histamine H3 antagonist-1 (Compound 10o) is a histamine H3 antagonist and a serotonin reuptake inhibitor, which can be used in depression research.
    Histamine H3 antagonist-1
  • HY-160677
    P2X4 antagonist-2 2055601-24-4
    P2X4 antagonist-2 is an antagonist for P2X4 with an IC50 of 24 nM.
    P2X4 antagonist-2
  • HY-160959
    AN317 946074-35-7
    AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP+. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB).
    AN317
  • HY-160978
    Timelotem 96306-34-2
    Timelotem (KC-7507 free base) is a representative of a class of 1, 2-cyclo1, 4-benzodiazepines. Timelotem shows significant antipsychotic properties. Timelotem produces sedative, anti-anxiety and anti-convulsant effects by enhancing the action of the neurotransmitter gamma-aminobutyric acid (GABA). Timelotem can be used in studies of schizophrenia and other mental disorders.
    Timelotem
  • HY-160980
    Sornidipine 95105-77-4
    Sornidipine is a calcium channel blocker. Sornidipine also reduces neurogenic inflammation. Sornidipine reduces the inflow of calcium ions into cells by blocking L-type calcium channels, thereby reducing the contraction of vascular smooth muscle, leading to vasodilation and decreased blood pressure. Sornidipine can be used to study the cardiovascular system especially in hypertension and related cardiovascular diseases.
    Sornidipine
  • HY-160991
    Menabitan 83784-21-8
    Menabitan (SP-204) is an inhibitor for phosphodiesterase 9 (PDE 9), which acts as a non-opioid analgesic agent. Menabitan lowers the intraocular pressure in rabbit model.
    Menabitan
  • HY-160997
    Prosulpride 68556-59-2
    Prosulpride (GRI 1665), a neuroleptics, can block selectively dopaminergic receptor.
    Prosulpride
  • HY-161042
    Neuroprotective agent 2 2996062-20-3
    Neuroprotective agent 2 (Compd 28) is a potent neuroprotective agent which has a protective effect in both salsolinol and glutamate-induced neurodegeneration models. Neuroprotective agent 2 reduces oxidative stress and caspase-3/7 activity in the glutamate model.
    Neuroprotective agent 2
  • HY-161084
    CSF1R-IN-18
    CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases.
    CSF1R-IN-18
  • HY-161090
    AMPA receptor modulator-7
    AMPA receptor modulator-7 (compound 36) is a modulator of AMPA receptor. AMPA receptor modulator-7 has oral activity and can penetrate the blood-brain barrier.
    AMPA receptor modulator-7
  • HY-161109
    Aβ42-IN-4 2387822-02-6
    Aβ42-IN-4 (compound 0043) degrades amyloid precursor protein (APP) and reduces Aβ42 production.
    Aβ42-IN-4
  • HY-161142
    Carbonic anhydrase/AChE-IN-1
    Carbonic anhydrase/AChE-IN-1 (compound 16) is a carbonic anhydrase and AChE inhibitor with Kis of 24.42 nM, 19.95 nM, and 5.07 nM for hCA I, hCA II, and AChE, respectively.
    Carbonic anhydrase/AChE-IN-1
  • HY-161143
    Carbonic anhydrase/AChE-IN-2
    Carbonic anhydrase/AChE-IN-2 (compound 19) is a selective acetylcholinesterase (AChE) and carbonic anhydrase (CA) inhibitor, with Ei of 5.07 nM, 24.42 nM and 19.95 nM for AChE, hCAI and hCAII, respectively.
    Carbonic anhydrase/AChE-IN-2
  • HY-161150
    AChE/BChE-IN-17
    AChE/BChE-IN-17 (compound 8m) is a potent and non-competitiveAChE and BChE inhibitor, with IC50 values of 125.06 nM and 119.68 nM, respectively. AChE/BChE-IN-17 also inhibits α-glucosidase, with an IC50 of 41050 nM.
    AChE/BChE-IN-17
  • HY-161156
    BChE-IN-26
    BChE-IN-26 (Compound 7b) is a selective AChE and BChE inhibitor with Ki value of 35 μM and 1.6 μM. BChE-IN-26 has cytotoxicity to human neuroblastoma (SH-SY5Y) cell line. BChE-IN-26 can be used for the research of Alzheimer’s disease.
    BChE-IN-26
  • HY-161174
    Carbonic anhydrase inhibitor 17 3033849-05-4
    Carbonic anhydrase inhibitor 17 (compound 7c) ,pyridazine-tethered sulfonamide, is a carbonic anhydrase II inhibitor with IC50 of 0.63 nM.
    Carbonic anhydrase inhibitor 17
  • HY-161240
    MAO-B-IN-30 82973-15-7 98.53%
    MAO-B-IN-30 (compound IS7) is a potent, selective and cross the blood-brain barrier MAO-B inhibitor with IC50 values of 19.176, 0.082 µM for MAO-A and MAO-B, respectively. MAO-B-IN-30 shows antiproliferative activity and non-cytotoxic. MAO-B-IN-30 reduces TNF-alpha, IL-6, NF-kB levels. MAO-B-IN-30 has the potential for the research of Parkinson's disease.
    MAO-B-IN-30
  • HY-161243
    AChE-IN-56
    AChe-IN-56 is an orally active inhibitor for acetylcholinesterase enzyme (AChE) with neuroprotective efficacy.
    AChE-IN-56
  • HY-161272
    Nav1.8-IN-6
    Nav1.8-IN-6 (Compound 2j) is a novel pyridinone amide Nav1.8 channel inhibitor. The IC50 values in the resting state and semi-activated state are 513.33 and 471.81 nM, respectively. Nav1.8-IN-6 has analgesic activity.
    Nav1.8-IN-6
Cat. No. Product Name / Synonyms Application Reactivity
  •  
  •